http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-PA04007183-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5d62b24bd9ee041f521ff3177003b86
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-59
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C303-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-277
filingDate 2002-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ccd7b873fd5cb824b5ab694c7ce0442
publicationDate 2006-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MX-PA04007183-A
titleOfInvention PHARMACEUTICAL COMPOSITION FOR THE CONTROL OF GLUCOSE IN BLOOD OF PATIENTS WITH TYPE 2 DIABETES.
abstract Pharmaceutical compositions of the active substances Glimepiride and Metformin or their salts such as hydrochloride, succinate fumarate, etc. are provided. for the control of blood glucose in patients with type 2 diabetes. To test the effectiveness of the combination, clinical studies were conducted that proved that there is not only an additive effect of the two drugs but also synergistic, compared to monotherapy using only some of the drugs of the combination. Consequently, the use of the combination is proposed as an effective and safe therapy for blood glucose control of patients with type 2 diabetes using different proportions of the active substances in the combinations, to adapt to the different needs of the patients.
priorityDate 2002-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4091
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3476
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419508054
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533847
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5793
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID160419
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419497074
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538597
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410072000
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID723

Total number of triples: 35.